Therapy for Helicobacter pylori in patients with nonulcer dyspepsia: A meta-analysis of randomized, controlled trials

L. Laine, P. Schoenfeld, M (Brian) Fennerty

Research output: Contribution to journalArticle

235 Citations (Scopus)

Abstract

Purpose: To assess the effect of eradication therapy for Helicobacter pylori on symptoms of nonulcer dyspepsia. Data Sources: Duplicate searches of bibliographic databases, reviews of proceedings of annual gastroenterology and H. pylori meetings from 1995 to 1999, reviews of reference lists, and contact with primary investigators and pharmaceutical manufacturers. Study Selection: Included studies 1) examined patients with nonulcer dyspepsia and H. pylori infection; 2) used combination therapy for H. pylori and a control therapy without efficacy against H. pylori; 3) were randomized, controlled trials; 4) lasted for at least 1 month after the end of therapy; and 5) assessed symptoms of nonulcer dyspepsia. Ten studies were included. Data Extraction: Independent, duplicate data extraction of the methodologic quality, population, intervention, study design, duration, and outcome of the trials. Data Synthesis: The odds ratio (OR) for treatment success in nonulcer dyspepsia with H. pylori eradication therapy compared with control therapy was 1.29 (95% CI, 0.89 to 1.89; P = 0.18). However, significant heterogeneity (P = 0.04) calls the validity of aggregating the data into question. Heterogeneity resolved with the exclusion of one study (OR, 1.07 [CI, 0.83 to 1.37]; P > 0.2). For predefined analysis of trials that used a specifically stated definition of dyspepsia (that is, upper abdominal pain or discomfort), the OR was 1.04 (CI, 0.80 to 1.35) without heterogeneity. For treatment that resulted in cure rather than persistent infection, the OR was 1.17 (CI, 0.87 to 1.59) without heterogeneity. Conclusion: This meta-analysis provides little support for the use of H. pylori eradication therapy in patients with nonulcer dyspepsia.

Original languageEnglish (US)
Pages (from-to)361-369
Number of pages9
JournalAnnals of Internal Medicine
Volume134
Issue number5
StatePublished - Mar 6 2001
Externally publishedYes

Fingerprint

Dyspepsia
Helicobacter pylori
Meta-Analysis
Randomized Controlled Trials
Odds Ratio
Therapeutics
Bibliographic Databases
Information Storage and Retrieval
Helicobacter Infections
Gastroenterology
Abdominal Pain
Research Personnel

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapy for Helicobacter pylori in patients with nonulcer dyspepsia : A meta-analysis of randomized, controlled trials. / Laine, L.; Schoenfeld, P.; Fennerty, M (Brian).

In: Annals of Internal Medicine, Vol. 134, No. 5, 06.03.2001, p. 361-369.

Research output: Contribution to journalArticle

@article{9563078a51bd4942a9c7dd1115ba2333,
title = "Therapy for Helicobacter pylori in patients with nonulcer dyspepsia: A meta-analysis of randomized, controlled trials",
abstract = "Purpose: To assess the effect of eradication therapy for Helicobacter pylori on symptoms of nonulcer dyspepsia. Data Sources: Duplicate searches of bibliographic databases, reviews of proceedings of annual gastroenterology and H. pylori meetings from 1995 to 1999, reviews of reference lists, and contact with primary investigators and pharmaceutical manufacturers. Study Selection: Included studies 1) examined patients with nonulcer dyspepsia and H. pylori infection; 2) used combination therapy for H. pylori and a control therapy without efficacy against H. pylori; 3) were randomized, controlled trials; 4) lasted for at least 1 month after the end of therapy; and 5) assessed symptoms of nonulcer dyspepsia. Ten studies were included. Data Extraction: Independent, duplicate data extraction of the methodologic quality, population, intervention, study design, duration, and outcome of the trials. Data Synthesis: The odds ratio (OR) for treatment success in nonulcer dyspepsia with H. pylori eradication therapy compared with control therapy was 1.29 (95{\%} CI, 0.89 to 1.89; P = 0.18). However, significant heterogeneity (P = 0.04) calls the validity of aggregating the data into question. Heterogeneity resolved with the exclusion of one study (OR, 1.07 [CI, 0.83 to 1.37]; P > 0.2). For predefined analysis of trials that used a specifically stated definition of dyspepsia (that is, upper abdominal pain or discomfort), the OR was 1.04 (CI, 0.80 to 1.35) without heterogeneity. For treatment that resulted in cure rather than persistent infection, the OR was 1.17 (CI, 0.87 to 1.59) without heterogeneity. Conclusion: This meta-analysis provides little support for the use of H. pylori eradication therapy in patients with nonulcer dyspepsia.",
author = "L. Laine and P. Schoenfeld and Fennerty, {M (Brian)}",
year = "2001",
month = "3",
day = "6",
language = "English (US)",
volume = "134",
pages = "361--369",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - Therapy for Helicobacter pylori in patients with nonulcer dyspepsia

T2 - A meta-analysis of randomized, controlled trials

AU - Laine, L.

AU - Schoenfeld, P.

AU - Fennerty, M (Brian)

PY - 2001/3/6

Y1 - 2001/3/6

N2 - Purpose: To assess the effect of eradication therapy for Helicobacter pylori on symptoms of nonulcer dyspepsia. Data Sources: Duplicate searches of bibliographic databases, reviews of proceedings of annual gastroenterology and H. pylori meetings from 1995 to 1999, reviews of reference lists, and contact with primary investigators and pharmaceutical manufacturers. Study Selection: Included studies 1) examined patients with nonulcer dyspepsia and H. pylori infection; 2) used combination therapy for H. pylori and a control therapy without efficacy against H. pylori; 3) were randomized, controlled trials; 4) lasted for at least 1 month after the end of therapy; and 5) assessed symptoms of nonulcer dyspepsia. Ten studies were included. Data Extraction: Independent, duplicate data extraction of the methodologic quality, population, intervention, study design, duration, and outcome of the trials. Data Synthesis: The odds ratio (OR) for treatment success in nonulcer dyspepsia with H. pylori eradication therapy compared with control therapy was 1.29 (95% CI, 0.89 to 1.89; P = 0.18). However, significant heterogeneity (P = 0.04) calls the validity of aggregating the data into question. Heterogeneity resolved with the exclusion of one study (OR, 1.07 [CI, 0.83 to 1.37]; P > 0.2). For predefined analysis of trials that used a specifically stated definition of dyspepsia (that is, upper abdominal pain or discomfort), the OR was 1.04 (CI, 0.80 to 1.35) without heterogeneity. For treatment that resulted in cure rather than persistent infection, the OR was 1.17 (CI, 0.87 to 1.59) without heterogeneity. Conclusion: This meta-analysis provides little support for the use of H. pylori eradication therapy in patients with nonulcer dyspepsia.

AB - Purpose: To assess the effect of eradication therapy for Helicobacter pylori on symptoms of nonulcer dyspepsia. Data Sources: Duplicate searches of bibliographic databases, reviews of proceedings of annual gastroenterology and H. pylori meetings from 1995 to 1999, reviews of reference lists, and contact with primary investigators and pharmaceutical manufacturers. Study Selection: Included studies 1) examined patients with nonulcer dyspepsia and H. pylori infection; 2) used combination therapy for H. pylori and a control therapy without efficacy against H. pylori; 3) were randomized, controlled trials; 4) lasted for at least 1 month after the end of therapy; and 5) assessed symptoms of nonulcer dyspepsia. Ten studies were included. Data Extraction: Independent, duplicate data extraction of the methodologic quality, population, intervention, study design, duration, and outcome of the trials. Data Synthesis: The odds ratio (OR) for treatment success in nonulcer dyspepsia with H. pylori eradication therapy compared with control therapy was 1.29 (95% CI, 0.89 to 1.89; P = 0.18). However, significant heterogeneity (P = 0.04) calls the validity of aggregating the data into question. Heterogeneity resolved with the exclusion of one study (OR, 1.07 [CI, 0.83 to 1.37]; P > 0.2). For predefined analysis of trials that used a specifically stated definition of dyspepsia (that is, upper abdominal pain or discomfort), the OR was 1.04 (CI, 0.80 to 1.35) without heterogeneity. For treatment that resulted in cure rather than persistent infection, the OR was 1.17 (CI, 0.87 to 1.59) without heterogeneity. Conclusion: This meta-analysis provides little support for the use of H. pylori eradication therapy in patients with nonulcer dyspepsia.

UR - http://www.scopus.com/inward/record.url?scp=0035814971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035814971&partnerID=8YFLogxK

M3 - Article

C2 - 11242496

AN - SCOPUS:0035814971

VL - 134

SP - 361

EP - 369

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -